



NEWS RELEASE

Athersys to Participate in Two Upcoming Investor Conferences

4/1/2022

Company presentations scheduled at the Locust Walk Stem Cell Conference, April 11, and at the Needham Healthcare Conference, April 13

CLEVELAND--(BUSINESS WIRE)-- Athersys, Inc. (Nasdaq: ATHX) announced today that William (B.J.) Lehmann, President and Chief Operating Officer, will present a corporate overview at the virtual Locust Walk Stem Cell Conference on Monday, April 11, 2022 at 2:00 p.m. ET. Mr. Lehmann will discuss the Company's investigational clinical product platform, MultiStem® (invimestrocel) cell therapy, which is in late-stage clinical development in the areas of ischemic stroke, acute respiratory distress syndrome (ARDS) and trauma.

Additionally, Dan Camardo, Chief Executive Officer, will present a corporate overview at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 10:15 a.m. ET. Mr. Camardo will discuss the Company's clinical programs and its preparations for potential commercialization of MultiStem. The Company's management team will also participate in one-on-one meetings with institutional investors during the Needham Healthcare Conference.

A live webcast of both presentations can be accessed by visiting '**Events & Presentations**' in the Investors Section on the Company's website. An archived replay of the webcast will be available on the Company's website after the

conference for a limited time.

Institutional investors interested in arranging a virtual meeting with the Company's management during either conference should contact ir@athersys.com.

About Athersys

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. Investors and others should note that we may post information about the Company on our website at www.athersys.com and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms. It is possible that the postings could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in the Company to review the information we post on our website at www.athersys.com and on our social media accounts. Follow Athersys on Twitter at www.twitter.com/athersys. Information that we may post about the Company on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. You should not place undue reliance on forward-looking statements contained on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

Ivor Macleod
Chief Financial Officer
Tel: (216) 431-9900
ir@athersys.com

Karen Hunady
Director of Corporate Communications & Investor Relations
Tel: (216) 431-9900
khunady@athersys.com

David Schull
Russo Partners, LLC

Tel: (212) 845-4271 or (858) 717-2310

David.schull@russopartnersllc.com

Peter Vozzo

ICR Westwicke

Tel: (443) 213-0505

peter.vozzo@westwicke.com

Source: Athersys, Inc.